Rx Risk Management Programs May Become Routine Element In FDA Reviews
Executive Summary
The establishment of "risk management" programs for pharmaceuticals may become a routine part of the FDA approval process.
You may also be interested in...
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
FDA To Study "Labeling Fatigue": Do Serial Changes Influence Prescribing?
FDA is planning an internal research effort to examine the concept of "labeling fatigue," which suggests that serial label changes or extensive warnings in the package insert have limited ability to alter prescribing behavior.